All doses of Eli Lilly’s weight reduction medicine Zepbound and Mounjaro can be found in america after greater than a 12 months of being in scarcity, in keeping with the Meals and Drug Administration’s (FDA) medicine scarcity database.
Till Friday, at the least 4 dosages of Mounjaro and Zepbound had been listed on the FDA’s web site as in scarcity within the U.S.
The company nonetheless lists a scarcity of the medicine total, nonetheless, which implies probably harmful compounded variations of that drug are nonetheless allowed in the marketplace.
Compounding pharmacies could make a medicine that’s basically a replica of a commercially obtainable drug if its lively substances are listed on the FDA’s drug scarcity listing.
Lilly has been warning sufferers about gross sales and social media posts involving phony or compounded variations of tirzepatide, the lively ingredient in Zepbound and Mounjaro.
Mounjaro is a diabetes drug, and FDA authorised Zepbound for weight reduction final 12 months. Its important competitor, Wegovy, remains to be in scarcity.
